Officials Cast Doubt on a Dementia Drug, but Human Trials ContinueThe regulatory approval path for simufilam is fraught with controversy and allegations of research misconduct.
The Future of Ozempic Will Be Riddled With DupesObesity drug shortages have driven people to risky, unregulated alternatives, posing serious health risks.